Friulimicin B is a naturally occurring antibiotic produced by a micro-organism, Actinoplanes friuliensis. It shows strong cidal activity against a number of Gram-positive pathogens which commonly cause serious infections in hospital patients and which are becoming more routinely acquired in the community.
Investigated for use/treatment in bacterial infection.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.